血清CEA水平与厄洛替尼治疗晚期非小细胞肺癌疗效的相关性分析

The correlation between serum level of CEA and curative effect after Erlotinib treatment in patients with advanced non-small cell lung cancer

目的:探讨血清CEA水平与EGFR-TKI药物厄洛替尼治疗晚期非小细胞肺癌疗效的相关性。方法:对60例晚期非小细胞肺癌患者二线采用厄洛替尼进行治疗,并在接受治疗前进行血清CEA水平的检测,同时对患者的预后与患者的性别、年龄、分期、病理类型以及CEA水平等进行分析。以50μg/L为分界线,将患者分为高CEA水平组以及低CEA水平组。结果:对2组患者治疗疗效比较,高CEA水平组患者其有效率为50.0%、稳定为33.3%、进展为16.7%;而低CEA水平组患者分别为14.6%、43.8%以及41.7%,2组患者治疗疗效差异有统计学意义(P<0.05)。对患者进行生存分析结果提示,高CEA水平患者其经过厄洛替尼治疗后有更长的无疾病进展时间以及生存时间(P<0.05)。结论:血清CEA水平可作为评估厄洛替尼治疗晚期非小细胞肺癌的疗效以及预后的生化指标。

Objective：To investigate the correlation between the serum levels of carcinoembryonic antigen（CEA）and patient＇s prognosis after EGFR-TKI（ Erlotinib） treatment in patients with advanced non-small cell lung cancer.Methods：All 60 patients with advanced non-small cell lung cancer were treated by EGFR-TKI drugs-Erlotinib,the serum levels of CEA in the patients were detected before treatment.The correlation between patients＇ prognosis and gender,age,cancer types,and CEA levels were analyzed.With 50μg / L as dividing line,the patients were divided into high CEA level group and low CEA level group.Results：The effective rate,stabilization rate,deterioration rate in high CEA level group were 50.0%,33.3%,16.7%,respectively,however,in low CEA level group were 14.6%,43.8%,41.7%,respectively,there were significant differences between two groups（ P〈0.05）.After Erlotinib treatment the patients in high CEA level group had longer disease-free advancement time,as compared with those in low CEA level group（ P〈0.05）.Conclusion：The serum level of CEA can be used as the biochemical indicator for evaluating the therapeutic effect of Erlotinib on advanced non-small cell lung cancer and the patients＇ prognosis.